simple Shrub, Aduro was chosen to work on gastric cancer because they have developed a vaccines for gastric cancer, while ADXS has focused on other cancers such as prostate. but you knew that already, didnt you?
Look at page 6 on ADXS' corporate presentation. We don't have a construct targeting gastric cancer, while ADRO does. I view the collaboration with ADRO positive with respect to our combo trial with Merck on prostate (i.e., if our combo data is showing positive signs, it may have pushed Merck to also do a trial with ADRO on gastric cancer given the promise of listeria vaccines in combo regimens).